ArticleScientific reports2023

Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen.

Yixiang Zhan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.